## **Core Concept**
The question tests knowledge of autoimmune diseases and their specific antibody associations. Anti-phospholipase receptor (anti-PLR) antibodies are specifically linked to a particular kidney disease. Understanding the target antigen and its clinical correlation is crucial.

## **Why the Correct Answer is Right**
The correct answer, **C. Membranous nephropathy**, is associated with anti-phospholipase receptor 3 (anti-PLA2R) antibodies. This is a well-established correlation where patients with membranous nephropathy often test positive for anti-PLA2R antibodies. These antibodies target the M-type phospholipase A2 receptor on the podocytes of the glomeruli, leading to immune complex deposition and characteristic changes in the glomerular basement membrane.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Minimal change disease is not associated with anti-PLA2R antibodies. It is characterized by the loss of foot processes of podocytes but lacks significant immune deposits on electron microscopy and is not linked to anti-PLA2R.
- **Option B:** Focal segmental glomerulosclerosis (FSGS) can have various causes, including genetic mutations and adaptive responses to injury, but it is not primarily associated with anti-PLA2R antibodies.
- **Option D:** IgA nephropathy, also known as Berger's disease, involves the deposition of IgA antibodies in the glomeruli but is not associated with anti-PLA2R antibodies.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **anti-PLA2R antibodies** are not only diagnostic for membranous nephropathy but also useful for monitoring disease activity and response to treatment. Their presence can help differentiate primary from secondary membranous nephropathy.

## **Correct Answer:** C. Membranous nephropathy.